Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chase Hobbs

Orthopaedic Surgery Lees Summit, MO Doctor of Osteopathy

NPI 1780248732 CMS profile 7230415

120 Ne Saint Lukes Blvd Ste 200, Lees Summit, MO 64086

Open in the dashboard

General payments

$131,063

136 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chase Hobbs of Lees Summit, MO is reported in the CMS Open Payments database as having received $131,063 across 136 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,338 61
2024 General $122,629 41
2023 General $1,499 25
2022 General $1,442 6
2021 General $84 2
2019 General $71 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chase Hobbs
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Chase Hobbs were reported at $5,338. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Chase Hobbs Orthopaedic Surgery median Middle half National median
2019 $71 $644 $140–$2,844 $163
2020 $0 $312 $75–$1,860 $114
2021 $84 $520 $117–$2,495 $132
2022 $1,442 $598 $128–$2,731 $149
2023 $1,499 $461 $128–$2,264 $160
2024 $122,629 $497 $134–$2,475 $164
2025 $5,338 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. LinkBio Corp $120,000 2 payments
  2. Stryker Corporation $4,018 72 payments
  3. Medacta USA, Inc. $2,543 19 payments
  4. Titan Surgical Group, LLC $1,524 5 payments
  5. Zimmer Biomet Holdings, Inc. $1,428 16 payments
  6. DePuy Synthes Sales Inc. $546 6 payments
  7. Medical Device Business Services, Inc. $348 4 payments
  8. Smith+Nephew, Inc. $192 2 payments
  9. Innovation Technologies Inc $106 1 payment
  10. Skeletal Dynamics Inc $103 2 payments
  11. Other $254 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $120,000 2 payments
  2. Food and Beverage $7,557 120 payments
  3. Travel and Lodging $2,066 11 payments
  4. Education $1,440 3 payments
Products named General payments · program years 2019–2025
  1. GMK Sphere $2,388 18 payments
  2. MAKO $1,803 30 payments
  3. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $667 6 payments
  4. GAMMA $601 9 payments
  5. Avenir $405 5 payments
  6. Persona $386 3 payments
  7. ICONIX $377 7 payments
  8. ATTUNE $322 2 payments
  9. VARIAX $304 7 payments
  10. COBRA $264 2 payments
  11. Other $3,793 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

180

Median for General Practice: 1,105

Drug cost

$1,077

Median for General Practice: $48,734

Branded share of claims

13.9%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 68 $434
Tramadol Hcl Generic 61 $229
Pantoprazole Sodium Generic 26 $202
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 13 $131
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 12 $81

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Records

136 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record